Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sitaxentan
Drug ID BADD_D02031
Description Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Indications and Usage Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure.
Marketing Status approved; investigational; withdrawn
ATC Code C02KX03
DrugBank ID DB06268
KEGG ID D07171
MeSH ID C106276
PubChem ID 216235
TTD Drug ID D0T1RG
NDC Product Code Not Available
UNII J9QH779MEM
Synonyms sitaxsentan | N-(4-chloro-3-methyl-5-isoxazolyl)-2-(3,4-(methylenedioxy)-6-methyl)phenylacetyl-3-thiophenesulfonamide | N-(4-chloro-3-methyl-5-isoxazolyl)-2-((4,5-(methylenedioxy)-O-toly)acetyl)-3-thiophenesulfonamide | TBC-11251 | TBC 11251 | TBC11251
Chemical Information
Molecular Formula C18H15ClN2O6S2
CAS Registry Number 184036-34-8
SMILES CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Conjunctival hyperaemia06.04.01.004--Not Available
Gastritis viral11.05.04.013; 07.19.03.006--Not Available
Ear congestion04.03.01.010--Not Available
Ear discomfort04.03.01.005--Not Available
Eye oedema06.08.03.013--Not Available
Eye pruritus06.04.05.006--Not Available
Lymphatic disorder01.09.01.003--Not Available
Nasal discomfort22.12.03.012--Not Available
Cardiac flutter02.03.02.012--Not Available
Oral pruritus07.05.05.002--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Protein urine present13.13.02.006--Not Available
Abdominal strangulated hernia24.04.08.013; 07.16.06.004--Not Available
Arthritis bacterial15.01.05.001; 11.02.01.004--Not Available
Thermal burn23.03.11.042; 12.05.04.001--
Haemorrhage24.07.01.002--Not Available
Connective tissue inflammation15.03.03.008--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Paranasal sinus hypersecretion22.04.06.004--Not Available
Peripheral artery aneurysm24.02.05.001--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Angiopathy24.03.02.007--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Joint injury15.01.08.019; 12.04.03.005--Not Available
Abdominal hernia07.16.06.005--Not Available
Arthritis infective11.01.01.003; 15.01.05.002--
Bladder disorder20.03.01.002--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Gastroenteritis bacterial11.02.01.018; 07.19.03.008--Not Available
The 12th Page    First    Pre   12 13 14    Next   Last    Total 14 Pages